MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.75

Buy Sell

Overview

Share price change

24h

Current

Min

3.75

Max

3.75

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+251.06% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-38M 217M
Previous open	3.75
Previous close	3.75

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 sty 2026, 16:17 UTC

Acquisitions, Mergers, Takeovers

Zurich Insurance Makes $10 Billion Bid for U.K. Specialist Insurer Beazley -- Update

19 sty 2026, 23:50 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Europe Relations -- Market Talk

19 sty 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

19 sty 2026, 22:29 UTC

Market Talk

China Infant Formula Market May Hold Up Despite Steep Drop in Births -- Market Talk

19 sty 2026, 22:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19 sty 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

19 sty 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19 sty 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

19 sty 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

19 sty 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19 sty 2026, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19 sty 2026, 17:09 UTC

Market Talk

Copper Rises in Spite of Softer Dollar, Trade Concerns -- Market Talk

19 sty 2026, 16:18 UTC

Market Talk

New Zealand Dollar Could Recover Against Swedish Krona -- Market Talk

19 sty 2026, 16:12 UTC

Market Talk

Norwegian Krone's Recent Gains Are Unlikely to Last -- Market Talk

19 sty 2026, 16:06 UTC

Acquisitions, Mergers, Takeovers

LVMH: Deal Completion Subject to Customary Closing Conditions and Expected to Close in Around Two Months

19 sty 2026, 16:04 UTC

Acquisitions, Mergers, Takeovers

LVMH: Both Parties Aim to Set Up Strategic Cooperation in the Retail Sector

19 sty 2026, 16:03 UTC

Acquisitions, Mergers, Takeovers

LVMH, CTG Duty-Free Also Entered Into a MoU

19 sty 2026, 16:02 UTC

Acquisitions, Mergers, Takeovers

LVMH: Subscription to Be Made Upon Completion of Transaction

19 sty 2026, 16:00 UTC

Acquisitions, Mergers, Takeovers

LVMH: Capital Increase by Subscribing to Newly Issued H-shares Listed in Hong Kong

19 sty 2026, 16:00 UTC

Market Talk

Term Premium on U.S. Treasurys Looks Too Low, Says Pictet AM -- Market Talk

19 sty 2026, 15:58 UTC

Acquisitions, Mergers, Takeovers

LVMH and the Miller Family Will Participate in a Capital Increase of CTG DutyFree

19 sty 2026, 15:57 UTC

Acquisitions, Mergers, Takeovers

LVMH: DFS Will Continue to Operate Its Other Luxury Travel Retail Operations Worldwide

19 sty 2026, 15:57 UTC

Acquisitions, Mergers, Takeovers

LVMH: Proceeds of Transaction Will Be Paid in Cash

19 sty 2026, 15:56 UTC

Acquisitions, Mergers, Takeovers

LVMH: CTG Duty-Free Will Run the Acquisition Through Its Subsidiary China Duty Free International Limited

19 sty 2026, 15:53 UTC

Acquisitions, Mergers, Takeovers

LVMH: Intangible Assets Include a Series of DFS Brands and IP for Exclusive Use in Greater China

19 sty 2026, 15:52 UTC

Acquisitions, Mergers, Takeovers

LVMH: CTG Duty-Free to Acquire the DFS Retail Stores in Hong Kong and Macau and Intangible Assets

19 sty 2026, 15:51 UTC

Acquisitions, Mergers, Takeovers

LVMH: DFS, CTG Duty-Free Reach Definitive Pact for CTG Duty-Free to Buy DFS' Travel Retail Unit in Hong Kong and Macau and Intangible Assets in Greater China

19 sty 2026, 15:39 UTC

Market Talk

Canadian Dollar's Underperformance Looks Overstretched -- Market Talk

19 sty 2026, 15:37 UTC

Market Talk

Bank of Canada Could Consider Cutting Rates if Underlying Inflation Slows Further -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

251.06% upside

12 Months Forecast

Average 13.2 USD 251.06%

High 25 USD

Low 8 USD

Based on 7 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.